Prevention of liver carcinogenesis by amarogentin through modulation of G1/S cell cycle check point and induction of apoptosis

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2424-2431

  Pal, Debolina ^a   Sur, Subhayan ^a   Mandal, Suvra ^b   Das, Ashes ^b   Roy, Anup ^c   Das, Sukta ^a   Panda, Chinmay Kumar ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b Department of Chemistry   (India)

^c NORTH BENGAL MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMAROGENTIN; ANTINEOPLASTIC AGENT; CARBON TETRACHLORIDE; CASPASE 3; CELL CYCLE PROTEIN; CYCLIN D1; DIETHYLNITROSAMINE; LIMD1 PROTEIN; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN CDC25A; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DYSPLASIA; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN INDUCTION; UPREGULATION; WEIGHT GAIN;

ANIMALS; APOPTOSIS; BODY WEIGHT; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHEMOPREVENTION; FEMALE; G1 PHASE; IRIDOIDS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; S PHASE;

EID: 84870356435     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs276     Document Type: Article

References (40)

1. Greenwald, P. et al. (1995) Chemoprevention. CA. Cancer J. Clin., 45, 31-49.
2. Suryawanshi, S. et al. (2009) Assessment of systemic interaction between Swertia chirata extract and its Bioactive constituents in rabbits. Phytother. Res., 23, 1036-1038.
3. Saha, P. et al. (2004) Evaluation of the anticarcinogenic activity of Swertia chirata Buch.Ham, an Indian medicinal plant, on DMBA-induced mouse skin carcinogenesis model. Phytother. Res., 18, 373-378.
4. Farazi, P.A. et al. (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer, 6, 674-687.
5. Nagasue, N. et al. (2001) Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br. J. Surg., 88, 515-522.
6. Fausto, N. (2000) Liver regeneration. J. Hepatol., 32, 19-31.
7. Zang, J.J. et al. (2011) P16 gene hypermethylation and hepatocellular carcinoma: a systematic review and meta-analysis. World J. Gastroenterol., 17, 3043-3048.
8. Kim, Y. et al. (2005) Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver. Toxicol. Pathol., 33, 175-180.
9. Plath, T. et al. (2002) Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J. Natl. Cancer Inst., 94, 129-142.
10. Shi, Y.Z. et al. (2000) Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. Clin. Cancer Res., 6, 4096-4100.
11. Saddic, L.A. et al. (2011) Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS ONE, 6, e19758.
12. Vita, M. et al. (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol., 16, 318-330.
13. Santoni-Rugiu, E. et al. (1998) Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res., 58, 123-134.
14. Alao, J.P. (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer, 6, 24.
15. Xu, X. et al. (2003) Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin. Cancer Res., 9, 1764-1772.
16. Zhang, M.F. et al. (2009) Correlation between expression of p53, p21/ WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J. Transl. Med., 7, 110.
17. Matsuda, Y. (2008) Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J. Gastroenterol., 14, 1734-1740.
18. Hui, A.M. et al. (1997) Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology, 25, 575-579.
19. Knights, C.D. et al. (2003) Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification. J. Biol. Chem., 278, 52890-52900.
20. Sharp, T.V. et al. (2004) LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc. Natl. Acad. Sci. U.S.A., 101, 16531-16536.
21. Senchenko, V.N. et al. (2010) Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer, 10, 75.
22. Huggins, C.J. et al. (2008) Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers. Cancer Lett., 267, 55-66.
23. Sinha, S. et al. (2008) Frequent alterations of hMLH1 and RBSP3/HYA22 at chromosomal 3p22.3 region in early and late-onset breast carcinoma: clinical and prognostic significance. Cancer Sci., 99, 1984-1991.
24. Ghosh, A. et al. (2010) Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance. Cancer Sci., 101, 1511-1520.
25. Ghosh, S. et al. (2010) LIMD1 is more frequently altered than RB1 in head and neck squamous cell carcinoma: clinical and prognostic implications. Mol. Cancer, 9, 58.
26. Singh, R.P. et al. (2002) Phytochemicals as cell cycle modulators: a less toxic approach in halting human cancers. Cell Cycle, 1, 156-161.
27. Sun, S.Y. et al. (2004) Apoptosis as a novel target for cancer chemoprevention. J. Natl. Cancer Inst., 96, 662-672.
28. Earnshaw, W.C. et al. (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem., 68, 383-424.
29. Saha, P. et al. (2006) Amarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis model. Cancer Lett., 244, 252-259.
30. Scorrano, L. et al. (2003) Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem. Biophys. Res. Commun., 304, 437-444.
31. Das, R.K. et al. (2004) Protective effect of diphenylmethyl selenocyanate against carbon tetrachloride-induced hepatotoxicity in vivo. J. Environ. Pathol. Toxicol. Oncol., 23, 287-296.
32. Shiota, G. et al. (1999) Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis, 20, 59-63.
33. Livak, K.J. et al. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-408.
34. Perrone, F. et al. (2006) Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin. Cancer Res., 12, 6643-6651.
35. Izumi, R. et al. (1992) Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival. J. Surg. Oncol., 49, 151-155.
36. Medda, S. et al. (1999) Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J. Antimicrob. Chemother., 44, 791-794.
37. Knudsen, E.S. et al. (1997) Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol. Cell. Biol., 17, 5771-5783.
38. Noh, J.H. et al. (2011) Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS ONE, 6, e28103.
39. Lee, T.K. et al. (2004) Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. Oncol. Rep., 12, 25-31.
40. Zang, J.J. et al. (2011) P16 gene hypermethylation and hepatocellular carcinoma: a systematic review and meta-analysis. World J. Gastroenterol., 17, 3043-3048.